Ensign Peak Advisors, Inc Nuvation Bio Inc. Transaction History

Ensign Peak Advisors, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $273,886 - $323,045	-175,568 Reduced 73.36%	63,763 $114,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $5,129 - $7,950	3,206 Added 1.36%	239,331 $397,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $17,996 - $26,780	10,712 Added 4.75%	236,125 $453,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $4.04 $4,446 - $61,945	-15,333 Reduced 6.37%	225,413 $505,000
Q2 2022 Aug 12, 2022	SELL	$3.24 - $5.85 $2.54 Million - $4.58 Million	-782,739 Reduced 76.48%	240,746 $780,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $618,171 - $1.19 Million	-134,385 Reduced 11.61%	1,023,485 $5.39 Million
Q4 2021 Feb 11, 2022	SELL	$7.75 - $10.05 $504,602 - $654,355	-65,110 Reduced 5.32%	1,157,870 $9.84 Million
Q3 2021 Nov 12, 2021	BUY	$7.78 - $10.0 $275,629 - $354,280	35,428 Added 2.98%	1,222,980 $12.2 Million
Q2 2021 Aug 13, 2021	BUY	$9.22 - $14.48 $3.12 Million - $4.91 Million	338,888 Added 39.93%	1,187,552 $11.1 Million
Q1 2021 May 12, 2021	BUY	$9.0 - $14.57 $7.64 Million - $12.4 Million	848,664 New	848,664 $8.87 Million

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.